1. Home
  2. LQDT vs PHAT Comparison

LQDT vs PHAT Comparison

Compare LQDT & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LQDT
  • PHAT
  • Stock Information
  • Founded
  • LQDT 1999
  • PHAT 2018
  • Country
  • LQDT United States
  • PHAT United States
  • Employees
  • LQDT N/A
  • PHAT N/A
  • Industry
  • LQDT Catalog/Specialty Distribution
  • PHAT Biotechnology: Pharmaceutical Preparations
  • Sector
  • LQDT Consumer Discretionary
  • PHAT Health Care
  • Exchange
  • LQDT Nasdaq
  • PHAT Nasdaq
  • Market Cap
  • LQDT 754.3M
  • PHAT 640.9M
  • IPO Year
  • LQDT 2006
  • PHAT 2019
  • Fundamental
  • Price
  • LQDT $24.84
  • PHAT $9.63
  • Analyst Decision
  • LQDT Strong Buy
  • PHAT Strong Buy
  • Analyst Count
  • LQDT 2
  • PHAT 5
  • Target Price
  • LQDT $38.50
  • PHAT $16.40
  • AVG Volume (30 Days)
  • LQDT 276.5K
  • PHAT 1.1M
  • Earning Date
  • LQDT 08-07-2025
  • PHAT 08-07-2025
  • Dividend Yield
  • LQDT N/A
  • PHAT N/A
  • EPS Growth
  • LQDT 23.09
  • PHAT N/A
  • EPS
  • LQDT 0.79
  • PHAT N/A
  • Revenue
  • LQDT $439,246,000.00
  • PHAT $81,859,000.00
  • Revenue This Year
  • LQDT $35.02
  • PHAT $195.03
  • Revenue Next Year
  • LQDT $9.90
  • PHAT $106.77
  • P/E Ratio
  • LQDT $31.43
  • PHAT N/A
  • Revenue Growth
  • LQDT 35.78
  • PHAT 3055.70
  • 52 Week Low
  • LQDT $19.87
  • PHAT $2.21
  • 52 Week High
  • LQDT $39.72
  • PHAT $19.71
  • Technical
  • Relative Strength Index (RSI)
  • LQDT 52.31
  • PHAT 61.95
  • Support Level
  • LQDT $24.37
  • PHAT $7.61
  • Resistance Level
  • LQDT $26.30
  • PHAT $9.76
  • Average True Range (ATR)
  • LQDT 0.68
  • PHAT 0.63
  • MACD
  • LQDT 0.14
  • PHAT -0.07
  • Stochastic Oscillator
  • LQDT 43.19
  • PHAT 93.95

About LQDT Liquidity Services Inc.

Liquidity Services Inc is an online auction marketplace. It manages and sells inventory and equipment for business and government clients by operating a network of e-commerce marketplaces that enable buyers and sellers to transact in an efficient, automated environment offering across different product categories. The company has four reportable segments: GovDeals, Capital Assets Group (CAG), Retail Supply Chain Group (RSCG), and Machinio. It generates majority of its revenue from Retail Supply Chain Group (RSCG) segment which consists of marketplaces that enable corporations located in the United States and Canada to sell excess, returned, and overstocked consumer goods. Geographically, a substantial portion the company's revenue is generated from its business in United States.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: